Paladin to Market Watson's Androderm in Canada

Watson Pharmaceuticals Inc. (Corona, CA) has granted Paladin Labs Inc. (Montreal) exclusive Canadian distribution rights for Androderm, Watson's testosterone transdermal delivery system for the treatment of male testosterone deficiency.

Androderm is manufactured at Watson's Salt Lake City facility. The product is sold in the United States by Watson and in other countries under various brand names through other Watson marketing partnerships.

Watson Pharmaceuticals develops, manufactures, and markets branded and off-patent pharmaceutical products.

Paladin Labs is a Canadian developer, marketer, and distributor of pharmaceuticals, currently offering products in urology, dermatology, rheumatology, and other specialty markets.

For more information: Lennie Ryer, Chief Financial Officer, Paladin Labs Inc., 6111 Royalmount Ave., Montreal, PQ, Canada H4P 2T4. Tel: 514-340-5067. Fax: 514-344-4675. E-mail: lryer@paladin-labs.com.

Edited by Jim Pomager